Skip to main content
Clinical Trials/NCT01569230
NCT01569230
Unknown
Not Applicable

Clinical Trial to Evaluate and Compare the Efficacy and Safety of Individualized and Standardized Acupuncture for Knee Osteoarthritis Patients: Randomized, Single-blind, Controlled Study

Eun Jung Kim1 site in 1 country250 target enrollmentOctober 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Osteoarthritis Knee
Sponsor
Eun Jung Kim
Enrollment
250
Locations
1
Primary Endpoint
WOMAC (Western Ontario and McMaster Universities) Scale change
Last Updated
14 years ago

Overview

Brief Summary

The purpose of this study is to verify the efficacy and safety of acupuncture treatments (Individualized, Standardized acupuncture) for patients with knee osteoarthritis (OA).

Detailed Description

The investigators targeted the patients with knee OA. After treatment in 4 groups - individualized acupuncture treatment, standardized acupuncture treatment, sham-needle treatment, and waiting groups - the investigators will compare the effects of pain relieving and daily performing improvement. So the investigators will confirm the efficacy of acupuncture, and further the best treatment method. In addition, the investigators are going to evaluate the safety of abnormal reaction during the treatment.

Registry
clinicaltrials.gov
Start Date
October 2010
End Date
December 2012
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Eun Jung Kim

Research professor

DongGuk University

Eligibility Criteria

Inclusion Criteria

  • At least 20 years of age, but below 80 years of age
  • Knee pain from OA in one or both knees in the last 3 months or more
  • Presence of knee OA diagnosed by an orthopedist based on American College of Rheumatology classification criteria
  • Knee pain from OA in one or both knees rated \> 4 cm on a 10 cm Visual Analog Scale (VAS)
  • An understanding of the objectives and methods of the clinical trial, and willingness in completing the consent form.
  • Those who are reliable and willing to cooperate in this test, and obey the restrictions for the next 3 months

Exclusion Criteria

  • Trauma to or surgery on the knee(s) within 6 months prior to enrollment, causing pain or functional problems
  • A history of prolotherapy, injection of hyaluronic acid or cortisone within the last 3 months
  • A physical or laboratory finding indicating infection, presence of an autoimmune disease, or inflammatory arthritis
  • Serious organic disease, and severe dysfunction due to the medical illness (e.g. Arrhythmia, Angina pectoris, Stroke, Asthma, etc.)
  • More severe pain in regions other than the knee joint.
  • When researchers evaluate that it is not appropriate to participate in this clinical test

Outcomes

Primary Outcomes

WOMAC (Western Ontario and McMaster Universities) Scale change

Time Frame: at 2nd(Baseline),8(after 3weeks of treatment),13th(after 6 weeks of treatment) and 14(follow up evaluation after 6 weeks from the last treatment) visit

WOMAC scale is checked by the patients. WOMAC scale is a tool to check of the disability, stiffness and pain by knee pain.

Secondary Outcomes

  • 100mm Pain Visual Analogue Scale(at 2(Baseline), 3, 4, 5, 6, 7, 8(after 3weeks of treatment), 9, 10, 11, 12, 13(after 6 weeks of treatment), and 14th(follow up evaluation after 6 weeks from the last treatment) visit)
  • 6 Minute walk test(at 2nd(Baseline),8(after 3weeks of treatment),13th(after 6 weeks of treatment) and 14(follow up evaluation after 6 weeks from the last treatment) visit)
  • WOMAC pain(at 2(Baseline), 3, 4, 5, 6, 7, 8(after 3weeks of treatment), 9, 10, 11, 12, 13(after 6 weeks of treatment), and 14th(follow up evaluation after 6 weeks from the last treatment) visit)
  • Investigator global assessment(IGA)(at 2(Baseline), 3, 4, 5, 6, 7, 8(after 3weeks of treatment), 9, 10, 11, 12, 13(after 6 weeks of treatment), and 14th(follow up evaluation after 6 weeks from the last treatment) visit)
  • Patient global assessment(PGA)(at 2(Baseline), 3, 4, 5, 6, 7, 8(after 3weeks of treatment), 9, 10, 11, 12, 13(after 6 weeks of treatment), and 14th(follow up evaluation after 6 weeks from the last treatment) visit)
  • Adverse Events(at 2(Baseline), 3, 4, 5, 6, 7, 8(after 3weeks of treatment), 9, 10, 11, 12, 13th(end of treatment) visit)

Study Sites (1)

Loading locations...

Similar Trials